Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pharmacogenomic approach to Alzheimer's disease.

Acta neurologica Scandinavica. Supplementum - 1 Jan 2000

Cacabelos R, Alvarez A, Fenández-Novoa L, Lombardi V R

Abstract excerpt

Single nucleotide polymorphisms (susceptibility genetics) and genomic point mutations (mendelian genetics) can be used in Alzheimer's disease (AD) for diagnostic, predictive and therapeutic purposes. Using a matrix genetic model, including APOE, PS1 and PS2 allelic variants, we have studied the distribution of 36 different genotypes in the AD population (N= 479) and the genotype-related cognitive response to a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Alzheimer Disease
Share to Apolipoproteins E

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cognition

Share to Drug Therapy, Combination

Share to Glycosides

Share to Presenilin-1

Share to Presenilin-2

Source

Identifiers

PMID: 11261800
DOI: 10.1034/j.1600-0404.2000.00302.x

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pharmacogenomic approach to Alzheimer's disease.PMID 11261800Read ↗

Pharmacogenomics for the treatment of dementia.Semantic proximity Read ↗

The application of functional genomics to Alzheimer's disease.Semantic proximity Read ↗

Pharmacogenetic Considerations in the Treatment of Alzheimer’s DiseaseSemantic proximity Read ↗

Opportunities in pharmacogenomics for the treatment of Alzheimer’s diseaseSemantic proximity Read ↗

Pharmacogenetic Basis for Therapeutic Optimization in Alzheimer’s DiseaseSemantic proximity Read ↗

Influence of pharmacogenetic factors on Alzheimer's disease therapeutics.Semantic proximity Read ↗

Diagnosis of Alzheimer's disease: defining genetic profiles (genotype vs phenotype).Semantic proximity Read ↗

Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment StrategiesSemantic proximity Read ↗

Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors.Semantic proximity Read ↗

Exploratory analysis of seven Alzheimer's disease genes: disease progression.Semantic proximity Read ↗

Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.Semantic proximity Read ↗

Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.